Navigation Links
Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems

TUSTIN and SAN DIEGO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc. today reported that it presented data from several antibody projects using the company's recently installed Single-Use Bioreactors (S.U.B.) at the Thermo Scientific BioProduction Optimization Workshop held this week in San Diego, California. In response to growing demand for its cGMP bioproduction services, Avid installed a HyClone 1000 L S.U.B. in its manufacturing suite in November 2008, complementing the HyClone 100 L S.U.B. that was already installed in Avid's Process Development unit at its production facilities in Tustin, California.

At the workshop, Avid researchers discussed their early successes using the 100 L S.U.B. and 1000 L S.U.B. systems. Avid senior vice president of bioprocess development and manufacturing Richard Richieri presented data on cell culture performance at both the 100 L and 1000 L scale, demonstrating that the process is scalable and that cell growth and production are very similar in the two systems. Avid's initial analysis of the antibody product also shows excellent comparability between these disposable units and traditional reactors.

"We installed our HyClone S.U.B. systems to help meet the rising demand for our biomanufacturing services," said Mr. Richieri. "Our experience to date with these systems has been very positive, and we welcomed the opportunity to share our insights at this workshop with other industry representatives. Avid's commitment to efficient production has led us to innovate in a number of areas, including installing our two HyClone S.U.B. systems and acquiring a ClonePix automated system for optimal clone selection. These new technologies have been very successful in reducing our processing costs and shortening project timelines."

The Thermo Scientific HyClone S.U.B. consists of a reusable stainless steel outer support container and S.U.B. BioProcess Container (BPC(R)) that integrates with existing bioreactor control systems, providing the advantages of single-use bioprocessing without having to install a complete new bioreactor system. The retrofit product replaces the stainless steel bioreactor vessel in existing bioreactor systems, making it a flexible, rapid and economic option to increase bioreactor capacity.

Avid Bioservices is a wholly owned subsidiary of Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM).

About Avid Bioservices

Avid Bioservices provides a comprehensive range of cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid manufactures cGMP commercial product, as well as clinical supplies for all phases of clinical trials. The company's comprehensive range of cGMP services includes cell banking, stability testing, clinical product manufacturing and purification, bulk packaging, final product filling and regulatory support. Avid also provides a variety of process development activities, including cell line optimization, analytical method development and product characterization. The company has over 10 years of antibody manufacturing experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes. Avid was recently named the first pre-approved U.S. contract manufacturer of the DSM/Crucell PER.C6(R) production system. For more information about Avid, visit

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus (HCV) infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

     Avid Bioservices           Media
     Candice Fliedner           GendeLLindheim BioCom Partners
     (714) 508-6188             Barbara Lindheim
                                (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
2. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
3. ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference
4. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
5. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
6. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
7. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
8. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
9. Medivation Presents New Data on Dimebons Novel Mechanism of Action
10. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
11. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):